Moreover, by evaluating the effect of their use alone and combined with several inhibitors, we found that volasertib combined with bempedoic acid showed the strongest synergistic anti-proliferative activity in pan-cancer cell lines, which may decrease the mRNA expression of ACACA and SREBF1 by disrupting de novo lipid synthesis. This evidence concerns the gene SREBF1 and cancer.